Trial Profile
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Mesoblast; Osiris Therapeutics
- 25 May 2021 Results presented in a Mesoblast Media Release.
- 25 May 2021 According to a Mesoblast media release, data published in the peer-reviewed journal Respiratory Research.
- 01 Jun 2020 Results presented in the Mesoblast Media Release.